A 42-year-old lung transplant patient with ganciclovir-resistant cytomegalovirus (CMV) infection

Transplant Infectious Disease

Volumn 1, Issue 3, 1999, Pages 218-225

  Basgoz, N ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiviral resistance; Cytomegalovirus; Ganciclovir

Indexed keywords

GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; CLINICAL OBSERVATION; CLINICAL STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; DIAGNOSIS; DISEASE TRANSMISSION; DONOR; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOLOGY; LEUKOPENIA; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATION; RISK FACTOR;

ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOPENIA; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TISSUE DONORS;

EID: 0033188242     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.1999.010310.x     Document Type: Conference Paper

References (25)

1. CHOU S. Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis 1999: 1: 105-114.
2. RUBIN RH. Infection in the organ transplant recipient. In: RUBIN RH, YOUNG LS, eds. Clinical Approach to Infection in the Compromised Host. New York: Plenum Press, 1994: 629-705.
3. RUBIN RH, TOLKOFF-RUBIN NE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 1993: 37: 617-724.
4. RUBIN RH, TOLKOFF-RUBIN NE. The problem of cytomegalovirus infection in transplantation. In: MORRIS PJ, TILNEY NL, eds. Progress in Transplantation. New York, NY: Churchill Livingstone Inc, 1984: 1: 89-114.
5. BASGOZ N, HIBBERD PL, TOLKOFF-RUBIN N, et al. Possible role of cytomegalovirus disease in the pathogenesis of post-transplant lymphoproliferative disorder. Presented at the 12th Annual Meeting of the American Society of Transplant Physicians, May 1993, Houston, Texas.
6. ERICE A. Resistance of human cytomegalovirus to antiviral drugs. Clin Micro Rev 1999: 12: 286-297.
7. DREW WL, MINER R, SALEH E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993: 1: 179-185.
8. CHOU S, GUENTZEL S, MICHELS KR, MINER RC, DREW WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995: 172: 239-242.
9. MARSCHNER IC, COLLER AC, COOMBS RW, et al. Use of changes in plasma levels of human immunodeficiency virus type I RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998: 77: 40-47.
10. FLETCHER C, SAWCHUK R, CHINNOCK B, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986: 40: 281-286.
11. KUPPERMANN BD, QUICENO JI, FLORES AGUILAR M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993: 168: 1506-1509.
12. SPECTOR SA, BUSCH DF, FOLLANSBEE S, et al. Pharmacokinetic, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995: 171: 1431-1437.
13. BIRON KK, FYFE JA, STANAT SC, et al. A human cytomegalovirus mutant resistant to the nucleoside analog 9-(2-hydroxy-1-(hydroxymethyl)ethoxymethyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci USA 1986: 83: 8769-8773.
14. DREW WL, MINER RC, BUSCH DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegaloviral infections. J Infect Dis 1991: 163: 716-719.
15. SHINKAI M, BOZZETTE SA, et al. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis 1997: 175: 302-308.
16. SMITH IL, HONG ML, PILCHER AM, et al. Development of resistant cytomegalovirus genotypes during oral ganciclovir prophylaxis/preemptive therapy, abstr H120, p. 349. In Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC.
17. JABS DA, ENGER C, DUNN JP, et al. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis 1998: 177: 770-773.
18. STUDIES OF OCULAR COMPLICATIONS OF AIDS (SOCA) IN COLLABORATION WITH AIDS CLINICAL TRIALS GROUP. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. J Infect Dis 1997: 176: 50-58.
19. GILBERT C, HANDFIELD J, TOMA E, et al. Emergence and prevalence of cytomegalovirus mutations associated with ganciclovir resistance in AIDS patients. AIDS 1998: 12: 125-129.
20. BOIVIN G, ERICE A, CRANE DD, et al. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993: 168: 332-335.
21. LURAIN NS, AMMONS HC, KAPELL KS, et al. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 1996: 62: 497-502.
22. ALAIN S, HONDERLICK P, GRENET D, et al. Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 1997: 63: 1533-1536.
23. ROSEN HR, BENNER KG, FLORA KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997: 63: 476-478.
24. PLOTKIN SA, DREW WL, FELSENSTEIN D, et al. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1, 3-dihydroxy-2-propoxymethyl) guanine. J Infect Dis 1985: 152: 833-834.
25. JACOBSON MA, KRAMER F, BASSIAKOS Y, et al. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical trials group protocol 151. J Infect Dis 1994: 170: 189-193.